Loading
companiesCompany
GSK
GSK makes Jemperli, Zejula, and the twice-approved myeloma ADC Blenrep.
Also called: Tesaro, Inc.TesaroBellus Health Inc. - a GSK companyBellus Health
Overview
GSK, based in London and listed as GSK, makes Jemperli, Zejula and the twice-approved myeloma antibody-drug conjugate Blenrep. Dostarlimab is best known for organ preservation in mismatch-repair-deficient rectal cancer, reported by Cercek in 2022, and for the RUBY trial in endometrial cancer; niraparib is its PARP inhibitor in ovarian cancer; belantamab mafodotin was re-approved in 2025; momelotinib was proved in MOMENTUM for myelofibrosis; and B7-H4 and B7-H3 ADCs come from Hansoh licences. OnCo also links it to the bivalent HPV vaccine, to WRN helicase in MSI-high cancers, and to Zai Lab and SR One. Whether dostarlimab can turn rectal organ preservation into a formal indication is the open question. Dostarlimab, niraparib and belantamab mafodotin have their own pages.
Headquarters
London, GB
Scorecard
All companies#14of 1244 companies, score 128
- approved products +48
- phase 3 +9
- phase 1/2 +2
- targets +14
- modalities +12
- regions +7
- 24-month regulatory events +6
- registry trials +30
8 approved, 3 in phase 3, 2 earlier, 7 targets, 971 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-07-28 | Jiangsu Hengrui Pharmaceuticals to GSK HRS-9821 (PDE3/4 inhibitor for COPD) plus options on up to eleven further programmes across respiratory, immunology, inflammation and oncology | Licence | $500m | up to about $12bn | source |
| 2025-01-13 | IDRx to GSK IDRX-42, KIT inhibitor for gastrointestinal stromal tumours | Acquisition | $1.0bn | up to $1.15bn | source |
| 2023-12 | Hansoh Pharmaceutical to GSK HS-20093 (GSK5764227), B7-H3 ADC | Licence | $185m | up to about $1.7bn | source |
| 2023-10-20 | Hansoh Pharmaceutical to GSK HS-20089 (GSK5733584), B7-H4 ADC | Licence | $85m | up to $1.485bn | source |
Type
Large pharma · GSK
Stage
Public
Website
ApprovedMonoclonal antibody (anti-PD-1)
Dostarlimab · Jemperli
Dostarlimab is a PD-1 blocker famous for making rectal cancer disappear without surgery in every patient with a mismatch-repair-deficient tumour.
ApprovedSmall-molecule PARP inhibitor
Niraparib · Zejula
Niraparib is a PARP inhibitor approved as maintenance for ovarian cancer regardless of BRCA status, and in prostate cancer with abiraterone.
ApprovedADC
Belantamab mafodotin · Blenrep
A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Velzatinib is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.
Phase 3antibody (INN stem -mab; form not stated in the registry record)
Cobolimab is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for non-small-cell lung cancer, melanoma and hodgkin lymphoma, with its target not yet stated publicly.
Phase 3small molecule
IDRX-42 is an experimental small-molecule drug from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.
Phase 2Monoclonal antibody
Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma.
ApprovedCytotoxic (topoisomerase-I inhibitor)
Topotecan · Hycamtin
Topotecan is the long-standing second-line chemotherapy for relapsed small-cell lung cancer, and now the comparator that new drugs must beat.
ApprovedAlkylating agent (nitrogen mustard)
Chlorambucil · Leukeran
Chlorambucil (Leukeran) is a gentle oral chemotherapy tablet used for decades in chronic lymphocytic leukaemia and low-grade lymphomas, mainly in older patients.
Approved5-HT3 receptor antagonist (antiemetic)
Ondansetron · Zofran
Ondansetron (Zofran) was the drug that made cisplatin-type chemotherapy bearable. It blocks the serotonin signal that triggers vomiting and is now a cheap generic tablet, dissolving wafer or injection used across cancer care.
Phase 2Oral focal adhesion kinase (FAK) inhibitor
GSK2256098 is a tablet that blocks an enzyme called FAK, which meningiomas missing the NF2 gene rely on. In the Alliance A071401 trial it slowed progression in recurrent NF2-mutant meningiomas, one of the first positive results for a targeted drug in this tumour.
ApprovedRecombinant virus-like particle vaccine (adjuvanted)
HPV bivalent vaccine (types 16 and 18) · Cervarix
Cervarix is a vaccine against HPV types 16 and 18, the two types that cause most cervical cancers, authorised in the EU in 2007 and the US in 2009 after the 18,000-woman PATRICIA trial showed near-complete protection against type-specific precancer. GSK withdrew it from the US in 2016, but it remains WHO-prequalified and used in national programmes, including single-dose schedules.
ApprovedSmall-molecule JAK1/JAK2/ACVR1 inhibitor
Momelotinib · Ojjaara / Omjjara
Momelotinib is the JAK inhibitor designed for anaemic myelofibrosis patients: it can improve haemoglobin while shrinking the spleen.
rctNew England Journal of Medicine 2025changed practice172 citations
Nonoperative management of mismatch repair-deficient tumors
For mismatch repair-deficient rectal cancer, six months of a single antibody now replaces chemotherapy, radiotherapy and an operation, and the same appears to be true for early-stage mismatch repair-deficient cancers of other organs.
rctThe Lancet 2023changed practice164 citations
MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
rctNew England Journal of Medicine 2023changed practice628 citations
RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer
Women with newly diagnosed advanced or recurrent endometrial cancer should receive a PD-1 antibody (dostarlimab or pembrolizumab) with their chemotherapy, and mismatch repair testing is now essential because women with dMMR tumours gain a very large and durable benefit. The gain in mismatch-repair-proficient tumours is real but smaller, and molecular classification (POLE, p53, MMR) is increasingly used to decide who benefits most.
translationalNew England Journal of Medicine 2022changed practice1,294 citations
Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency
Cercek's dostarlimab study is the clearest demonstration that immunotherapy can replace surgery in a solid tumour: patients with dMMR rectal cancer can keep their rectum and avoid the permanent effects of pelvic radiotherapy and surgery. Non-operative management after PD-1 blockade is now in guidelines for this group, and MMR testing before treatment of rectal cancer is essential. The approach applies only to the 5-10% of rectal cancers that are dMMR.
rctThe Lancet 2009changed practice1,155 citations
Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis
This is the efficacy evidence behind the EU (2007) and US (2009) approvals of Cervarix. The gap between near-complete type-specific protection and the 30 percent overall effect in the whole cohort is the argument for vaccinating before sexual debut, where the effect was 70 percent.
Similar pages
- IdeaA funded programme of organ-preservation trials to avoid radical surgery
Shares A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer, A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202, A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma, Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer.
- CancerRelapsed or refractory multiple myeloma
Shares Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple, Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM, Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM, Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM.
- TechnologyAntiemetics for chemotherapy-induced nausea and vomiting
Shares Ondansetron, A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas, All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo, China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame.
- TreatmentDexamethasone
Shares A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme, Study 3 (rolapitant, moderately emetogenic chemotherapy), A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult, A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas.
- CancerMismatch-repair-deficient endometrial cancer
Shares A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors, GARNET, A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC), RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer.
- CancerMismatch-repair deficient (MSI-high) colorectal cancer
Shares A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors, A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China, A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer, A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors.
cancers
fronts
targets
drugs
ApprovedADC
Belantamab mafodotin · Blenrep
ApprovedAlkylating agent (nitrogen mustard)
Chlorambucil · Leukeran
Phase 3antibody (INN stem -mab; form not stated in the registry record)
ApprovedMonoclonal antibody (anti-PD-1)
Dostarlimab · Jemperli
Phase 2Monoclonal antibody
Phase 2Oral focal adhesion kinase (FAK) inhibitor
ApprovedRecombinant virus-like particle vaccine (adjuvanted)
HPV bivalent vaccine (types 16 and 18) · Cervarix
Phase 3small molecule
ApprovedSmall-molecule JAK1/JAK2/ACVR1 inhibitor
Momelotinib · Ojjaara / Omjjara
ApprovedSmall-molecule PARP inhibitor
Niraparib · Zejula
Approved5-HT3 receptor antagonist (antiemetic)
Ondansetron · Zofran
ApprovedCytotoxic (topoisomerase-I inhibitor)
Topotecan · Hycamtin
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
companies
trials
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyA Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and DexamethasA Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerA Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerA Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in ChinaA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate CancerA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerA Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerA Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory MultA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmeA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsA Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsA Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyeloAlliance A071401China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and DexameCOMBI-dEfficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseEfficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyExtended Access of Momelotinib in Adults With MyelofibrosisFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPCGARNETJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and DexMOMENTUMPATRICIAPlatform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory MultipleStudy 3 (rolapitant, moderately emetogenic chemotherapy)Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerStudy of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory MultipleSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants WiSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMand 3 more →
roadmaps
key papers
Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiencyEfficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysisMOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitorNonoperative management of mismatch repair-deficient tumorsRUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer